Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2003
11/18/2003US6649622 Treating diabetes, especially Type II diabetes
11/18/2003US6649619 Compounds
11/18/2003US6649616 For therapy and prophylaxis of cardiovascular disorders caused by ischaemia
11/18/2003US6649611 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
11/18/2003US6649604 Analgesics; antidiabetic agents; antiinflamamtory agents
11/18/2003US6649603 For therapy of metabolic disorders related to insulin resistance or hyperglycemia
11/18/2003US6649601 Bisphosphonic compound
11/18/2003US6649600 2,6-Dioxo or dithioxy-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo derivatives; highly potent and selective diuretics
11/18/2003US6649421 Antigen binding protein; use in diagnosis and treatment of cardiac infarction, stroke, arterial occlusion disease and kidney failure due to endothelial dysfunction
11/18/2003US6649391 Isolated polynucleotide encoding a polypeptide of given sequence; dephosphorylates MAP(mitogen activated protein)-kinase; used for modulating cell proliferation, differentiation and survival
11/18/2003US6649366 Methods and compositions related to modulators of annexin and cartilage homeostasis
11/18/2003US6649172 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants
11/14/2003CA2428516A1 Slowly digestible starch product
11/14/2003CA2428514A1 Resistant starch prepared by isoamylase debranching of low amylose starch
11/13/2003WO2003093456A1 Soya cell strains with high isoflavone content
11/13/2003WO2003093317A1 Antibody to human insulin-like growth factor
11/13/2003WO2003093311A1 Proteins with deglycating activities and methods of using same
11/13/2003WO2003093287A1 Novel method for preparing alpha-glycosylceramides, novel alpha-glycosylceramide derivatives and their uses
11/13/2003WO2003093267A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003093231A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
11/13/2003WO2003093222A1 Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092726A1 Combination of insulin and a thiazolidinedione derivative, and use thereof for treating diabetes
11/13/2003WO2003092722A1 7-HYDROXY-16α-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16α-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF
11/13/2003WO2003092715A2 Proteins involved in the regulation of energy homeostasis
11/13/2003WO2003092710A1 Pharmaceutical compositions comprising an extract of pelvetia siliquosa for the prevention or the treatment of liver disease, diabetes and diabetic complications
11/13/2003WO2003092709A1 Method for producing preparations rich in tocotrienol
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092694A1 Treatment of diabetes and diabetic complications with nhe-1 inhibitors
11/13/2003WO2003092693A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092682A1 Zonisamide use in obesity and eating disorders
11/13/2003WO2003092679A1 Preparation of phosphatase inhibitors
11/13/2003WO2003092678A1 1-substituted imidazole derivatives as nos inhibitors
11/13/2003WO2003092670A1 Bombesin antagonists
11/13/2003WO2003092660A1 Monocompartment osmotic controlled drug delivery system
11/13/2003WO2003092659A1 Oral dosage forms comprising fenofibrate
11/13/2003WO2003092647A2 Transport system in biological systems
11/13/2003WO2003092614A2 Lipid removal from the body
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092603A2 Composition and method for reducing post-prandial blood glucose
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092585A2 Controlled release compositions of estradiol metabolites
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003080056A3 Fine particle size pioglitazone
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003063821A3 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
11/13/2003WO2003061551A3 Ex-vivo gene therapy of diabetes using iap polypeptides
11/13/2003WO2003040691A3 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003028727A9 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
11/13/2003WO2003022871A3 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
11/13/2003WO2003022360A3 Thermotherapy via targeted delivery of nanoscale magnetic particles
11/13/2003WO2003018059A3 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002072888A3 Polymorphisms in the human cmoat gene and uses thereof
11/13/2003WO2002048715A3 Inflammatory markers for detection and prevention of diabetes mellitus
11/13/2003WO2002032874A8 Substituted heterocyclic compounds for treating multidrug resistance
11/13/2003US20030213003 Preparing and recoverng genetically engineered fusion protein for treating diabetes
11/13/2003US20030212279 Anticholesterol agents
11/13/2003US20030212273 Pyrrolo [2,3-D] pyrimidine compounds
11/13/2003US20030212140 Analgesics; central nervous system disorders
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212118 Obesity
11/13/2003US20030212104 Treatment of diabetes and diabetic complications with NHE-1 inhibitors
11/13/2003US20030212100 Antidiabetic agnets; insulin resistance
11/13/2003US20030212074 Phosphate transport inhibitors
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212070 Dietetics; cardiovascular disorders; hypotensive agents; psychological disorders
11/13/2003US20030212067 Bone disorders; rheumatic diseases; wound healing agents
11/13/2003US20030212066 1-Sulfonyl pyrrolidine derivatives
11/13/2003US20030212062 Morpholinone and morpholine derivatives and uses thereof
11/13/2003US20030212055 Cinnoline compounds
11/13/2003US20030212036 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis
11/13/2003US20030211997 Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same
11/13/2003US20030211993 Control cell proliferation, cell differentiation; culture product
11/13/2003US20030211986 Protein a compositions and methods of use
11/13/2003US20030211613 Methods of altering calcium transport
11/13/2003US20030211608 Antisense modulation of glycogen synthase kinase 3 beta expression
11/13/2003US20030211540 Treatment of insulin resistance
11/13/2003US20030211533 Method for testing a therapeutic or preventive agent for hyperlipidemia
11/13/2003US20030211529 Human Eag2
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211493 Comprises membrane protein for diagnosis, prevention and treatment of infections, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders
11/13/2003US20030211176 Using plant extract; hot water extraction
11/13/2003US20030211175 Binding to thaumalin protein; plant extracts; reduce glucose concentration
11/13/2003US20030211106 Binding tumor necrosis factor to antibody
11/13/2003CA2703698A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003CA2487693A1 Method for producing preparations rich in tocotrienol
1 ... 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 ... 1298